Browsing Tag
ACIP
3 posts
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
ACIP expands Pfizer’s ABRYSVO vaccine guidance to include at-risk adults aged 50–59
Pfizer's RSV vaccine ABRYSVO now recommended for at-risk adults aged 50–59. Learn what it means for public health and Pfizer’s expanding vaccine portfolio.
GSK secures FDA approval for 5-in-1 meningococcal vaccine to expand protection for adolescents
GSK has received approval from the US Food and Drug Administration (FDA) for PENMENVY, a 5-in-1 meningococcal vaccine…